Drugs / HAVRIX 720 Junior
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06298708 Comparator | Apr → Dec 2024 | hepatitis A virus infection | Chiang Mai University | Completed | No outcome recorded |
| Phase 3 | NCT05613127 Comparator | Dec 2022 → Jul 2024 | hepatitis A virus infection | Boryung Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Havrix 720 Junior | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06298708 ↗ |
| Modality | Vaccine | “inactivated hepatitis A vaccine” NCT05613127 ↗ |
| Route | Intramuscular | “IM injection of 0.5mL” NCT05613127 ↗ |